Detailed dose evidence documented for Eptifibatide in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
ACS: 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by 2.0 mcg/kg/min IV infusion. PCI: add second 180 mcg/kg bolus at 10 min. Infusion continues until discharge or up to 72-96 h (ACS) or 18-24 h post-PCI. Renal impairment (CrCl less than 50 mL/min): reduce infusion to 1 mcg/kg/min.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
IMPACT II used 135 mcg/kg bolus + 0.5-0.75 mcg/kg/min (lower than current approved dose). Higher doses were required to achieve >80% receptor occupancy, supporting the 180/2/180 regimen.
Not established
What is not established
STEMI: not an independent FDA-approved indication (studied in TITAN-TIMI 34, IMPACT-AMI but not labeled).
Dialysis-dependent patients: contraindicated in the US per current label.